Nuvectis Pharma, Inc.
NASDAQ: NVCT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ron Bentsur
- Employees
- 13
- Headquarters
- Fort Lee, United States
- IPO year
- 2022
- Market cap
- $649.3M
- Website
- https://www.nuvectis.com
Loading NVCT…
Loading profile data…Frequently asked questions about NVCT
What does Nuvectis Pharma, Inc. (NVCT) do?
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another pro...
Where does NVCT trade?
Nuvectis Pharma, Inc. (NVCT) trades on the NASDAQ Capital Market.
What sector is NVCT in?
Nuvectis Pharma, Inc. (NVCT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Nuvectis Pharma, Inc.?
Ron Bentsur is the chief executive officer of Nuvectis Pharma, Inc. (NVCT).
Where is Nuvectis Pharma, Inc. headquartered?
Nuvectis Pharma, Inc. is headquartered in United States.
Does NVCT pay a dividend?
Nuvectis Pharma, Inc. (NVCT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NVCT go public?
Nuvectis Pharma, Inc. (NVCT) completed its initial public offering in 2022.